By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...